Connective Tissue Disease Associated With Interstitial Lung Disease Market Set to Grow Through 2034 as Diagnosis Rates and Emerging Biologics Expand Treatment Options - DelveInsight

DelveInsight's "Connective Tissue Disease Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast - 2034" report offers an in-depth understanding of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), including historical and forecasted epidemiology as well as market trends across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Get a Free sample for the CTD-ILD Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the CTD-ILD Market Report

• Across the 7MM, roughly 1.16 million people were living with diagnosed CTD-ILD as of 2023, with the broader diagnosed ILD population reaching about 293 thousand cases; both figures are projected to climb through 2034.
• The US carried the largest treatment market among the 7MM in 2023, worth around USD 1.04 billion, and is expected to keep expanding over the forecast window.
• Treatment for CTD-ILD spans corticosteroids, immunosuppressants, biologics, DMARDs, and antifibrotic agents such as OFEV (nintedanib); biologics held the largest share of spending in 2023, at roughly USD 842 million across the 7MM.
• OFEV remains the cornerstone approved therapy, generating about USD 530 million in 7MM sales in 2023 as a treatment for systemic-sclerosis-associated ILD and other progressive fibrosing CTD-ILDs.
• GlaxoSmithKline's BENLYSTA (belimumab), currently in Phase II development for this indication, is anticipated to enter the US market by 2027, followed by launches in the EU4/UK by 2028 and Japan by 2029, and is expected to help ease the disease burden in the years ahead.
• By country, the US had approximately 132 thousand diagnosed prevalent CTD-ILD cases in 2023, the largest share among the 7MM.
• Among the European markets, the UK led with about 27 thousand diagnosed cases, followed by Germany at roughly 25 thousand, while Spain had the smallest population at around 11 thousand.
• Japan accounted for about 68 thousand diagnosed prevalent cases in 2023, close to a quarter of the total 7MM population.
• Within the US, the breakdown by CTD subtype in 2023 showed pSS-ILD as the most common (~38 thousand cases), followed by SSc-ILD (~31 thousand), other CTD-ILD subtypes (~30 thousand), RA-ILD (~20 thousand), DM/PM-ILD (~8 thousand), and SLE-ILD (~5 thousand).
• Key CTD-ILD Companies: Boehringer Ingelheim, Roche, Genentech, Bristol Myers Squibb, Novartis, Pfizer, Gilead Sciences, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Merck & Co., Sanofi, Eli Lilly, AbbVie, Celgene (part of BMS), Vertex Pharmaceuticals, Biogen, Amgen, Takeda, Daiichi Sankyo, Astellas Pharma, and others.
• Key CTD-ILD Therapies: OFEV (nintedanib), ACTEMRA (tocilizumab), and the emerging candidate BENLYSTA (belimumab), among other agents in earlier-stage development.

CTD-ILD Overview

Interstitial lung disease (ILD) describes a broad family of lung disorders marked by inflammation and/or scarring of lung tissue, arising from known causes (drugs, environmental or occupational exposure, systemic disease) or unknown causes (idiopathic pneumonias, granulomatous conditions, and related disorders). Connective tissue disease (CTD) is a group of systemic autoimmune conditions including rheumatoid arthritis, lupus, Sjögren's syndrome, inflammatory myopathies, systemic sclerosis, and mixed connective tissue disease. When CTD leads to lung scarring and inflammation, the resulting CTD-ILD can impair oxygen exchange and bring on breathlessness, cough, and fatigue.

To know in detail about the CTD-ILD market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here; CTD-ILD Market Forecast:
https://www.delveinsight.com/report-store/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

CTD-ILD Epidemiology

The epidemiology chapter of the report tracks historical, current, and forecasted trends across the 7MM from 2020 through 2034, segmented by total ILD prevalence, total diagnosed ILD prevalence, total diagnosed CTD-ILD prevalence, and subtype-specific diagnosed prevalence.

CTD-ILD Epidemiology Segmentation

• Total Prevalent Cases of Interstitial Lung Disease
• Total Diagnosed Prevalent Cases of ILD
• Total Diagnosed Prevalent Cases of CTD-ILD
• Type-specific Diagnosed Prevalent Cases of CTD-ILD (pSS-ILD, SSc-ILD, RA-ILD, DM/PM-ILD, SLE-ILD, and other subtypes)

Download the report to understand which factors are driving CTD-ILD epidemiology trends @ CTD-ILD Epidemiology Forecast:
https://www.delveinsight.com/report-store/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

CTD-ILD Diagnosis

Diagnosing CTD-ILD relies on a combination of clinical findings, imaging, and autoantibody testing, since plain chest X-rays lack sensitivity. High-resolution CT (HRCT) is the diagnostic gold standard, with prone imaging sometimes catching very early disease. Because there's no standardized monitoring protocol, distinguishing true disease progression from infection or drug-related lung changes remains difficult in the absence of reliable biomarkers. Diagnosis is frequently delayed given the wide range of presenting symptoms, and pulmonary involvement can either precede or follow the onset of rheumatic symptoms, underscoring the need for early recognition and a multidisciplinary care approach.

CTD-ILD Drugs Uptake and Pipeline Development Activities

The report's drug-uptake analysis covers how recently launched and soon-to-launch CTD-ILD therapies are being adopted, including patient share by therapy and sales trends for each drug. It also benchmarks products against one another by market share and evaluates pipeline programs, corporate collaborations, licensing deals, and patent activity for therapies still in development.

CTD-ILD Therapies and Key Companies

• OFEV (nintedanib): Boehringer Ingelheim
• ACTEMRA (tocilizumab): Approved in 2021 for use in SSc-ILD.
• BENLYSTA (belimumab): GlaxoSmithKline

Discover more about therapies set to grab major CTD-ILD market share @ CTD-ILD Treatment Landscape:
https://www.delveinsight.com/report-store/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

CTD-ILD Market Outlook

CTD-ILD sits at the intersection of systemic autoimmune disease and progressive lung fibrosis, and current treatment, corticosteroids, immunosuppressants such as cyclophosphamide, mycophenolate mofetil, methotrexate, and cyclosporine, plus antifibrotics like nintedanib and pirfenidone and biologics like tocilizumab, only partially addresses patient needs. No therapy today effectively treats the full range of CTD-ILD subtypes, and the evidence base is limited by a shortage of randomized controlled trials, leaving meaningful room for new entrants such as GSK's belimumab program.

• The CTD-ILD therapeutics market across the 7MM was valued at approximately USD 1.5 billion in 2023.
• The US represented roughly 70% of total 7MM market value that year.
• Germany led the EU4/UK grouping at close to USD 84 million, while Spain trailed at about USD 38 million.
• Japan's market stood at roughly USD 136 million, or about 9% of the 7MM total.
• Belimumab's anticipated 2027 US launch is projected to reach a peak share near 7%, with a medium-fast, roughly seven-year climb to peak uptake.

CTD-ILD Market Drivers

• A persistent lack of any single therapy that fully addresses the diverse CTD-ILD subtypes leaves substantial unmet need for new mechanisms of action.
• Off-label immunosuppressive regimens can stabilize lung function but rest on a thin base of controlled trial evidence, motivating continued drug development.

CTD-ILD Market Barriers

• High treatment costs remain a central obstacle, pushing some patients away from consistent care and straining payer systems.
• Diagnostic delay, driven by CTD-ILD's varied and overlapping symptoms, continues to limit how early patients can start effective therapy.

Scope of the CTD-ILD Market Report

• Study Period: 2020-2034
• Coverage: 7MM
• Key CTD-ILD Companies: Boehringer Ingelheim, Roche, Genentech, Bristol Myers Squibb, Novartis, Pfizer, Gilead Sciences, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Merck & Co., Sanofi, Eli Lilly, AbbVie, Celgene, Vertex Pharmaceuticals, Biogen, Amgen, Takeda, Daiichi Sankyo, Astellas Pharma, and others.
• Key CTD-ILD Therapies: OFEV (nintedanib), ACTEMRA (tocilizumab), BENLYSTA (belimumab), and others in development.
• Therapeutic Assessment: Current marketed and emerging CTD-ILD therapies.
• Market Dynamics: CTD-ILD market drivers and barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's Five Forces, market entry strategies.
• Additional Coverage: CTD-ILD unmet needs, KOL views (drawn from 50+ contacted and 15+ interviewed opinion leaders across institutions in the US, Germany, France, Italy, the UK, and Japan), analyst views, and market access and reimbursement analysis.

Table of Contents

• Connective Tissue Disease-Associated Interstitial Lung Disease Market Key Insights
• Connective Tissue Disease-Associated Interstitial Lung Disease Market Report Introduction
• Connective Tissue Disease-Associated Interstitial Lung Disease Market Overview
• Connective Tissue Disease-Associated Interstitial Lung Disease Epidemiology and Market Forecast Methodology
• Connective Tissue Disease-Associated Interstitial Lung Disease Market Executive Summary
• Connective Tissue Disease-Associated Interstitial Lung Disease Market Key Events
• Connective Tissue Disease-Associated Interstitial Lung Disease Disease Background and Overview
• Connective Tissue Disease-Associated Interstitial Lung Disease Epidemiology and Patient Population
• Connective Tissue Disease-Associated Interstitial Lung Disease Patient Journey
• Connective Tissue Disease-Associated Interstitial Lung Disease Marketed Therapies
• Connective Tissue Disease-Associated Interstitial Lung Disease Emerging Therapies
• Connective Tissue Disease-Associated Interstitial Lung Disease Market Analysis (7MM)
• Connective Tissue Disease-Associated Interstitial Lung Disease Key Opinion Leaders (KOL) Views
• Connective Tissue Disease-Associated Interstitial Lung Disease SWOT Analysis
• Connective Tissue Disease-Associated Interstitial Lung Disease Unmet Needs
• Connective Tissue Disease-Associated Interstitial Lung Disease Market Access and Reimbursement
• Appendix
• DelveInsight Capabilities
• Disclaimer

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.